Although phenotypic cellular screening has recently been used to drive antimalarial drug discovery, there continues to be a clear need for rational target-based drug discovery. This is especially true when appropriate high-throughput cellular assays are lacking. Such is the case for drug discovery efforts that aim to provide a replacement for primaquine, a drug with known toxicity that is the only agent that eliminates Plasmodium vivax liver stage infection and blocks gametocyte transmission. At present, there are no known chemically validated parasite protein targets that are critical to replicating or hypnozoite liver stages as well as asexual blood and gametocyte stages, and that could be used in biochemical screens of large compound libraries. The genomes of Plasmodium parasite species encode over 5,500 proteins, many of which remain uncharacterized. Our central hypothesis is that a wealth of novel, chemically validated multi-stage antimalarial targets still remain to be discovered. To test this we propose to focus on five recently discovered, chemically distinct scaffolds with broad ranging activity against the parasite lifecycle, including liver and asexual blood stages. We will further prioritize compounds by determining which of these are active against P. falciparum asexual blood stages from multidrug-resistant strains, gametocytes, and P. vivax hepatic forms. To generate low-level resistance, we will expose P. falciparum parasites (three independent selections, against three members of each scaffold series) to sublethal concentrations of compound. The genomes of drug-resistant clones will be examined by next-generation sequencing with paired-end reads (yielding ~100X coverage) to identify the complete suite of genetic changes that have emerged in each clone during chemical selection. Based on our preliminary data, we expect to find a statistically significant enrichment of newly emerged mutations in only one gene for each scaffold, when considering the whole-genome sequence for all nine resistant strains created per scaffold family. The importance of the candidate targets wil be verified by introducing genetic changes into drug-sensitive P. falciparum parasites and testing for gain of resistance, or conversely removing candidate mutations and testing for loss of resistance. Transfection experiments will include zinc finger nucleases, which constitute a major breakthrough in their ability to mediate highly efficient gene editing in P. falciparum. We will alo seek to determine whether the identified gene is the target of the small molecule or a gene involved in resistance through a detailed molecular characterization. The work will provide the malaria community with a systematic picture of how P. falciparum acquires drug resistance, and is expected to yield several new validated targets that can be used in drug development efforts focused on finding new radical-cure agents. This research, which is consistent with NIAID's mission statement, promises to leverage chemical scaffolds active against Plasmodium parasites to define new targets for the development of broad intervention strategies based on chemoprophylaxis and curative treatment of malarial infections.
Emerging drug resistance creates a constant need to innovate in the discovery of antimicrobial agents. Here, we propose to leverage recent chemical advances in the identification of inhibitors active against the human-specific parasitic pathogen Plasmodium falciparum to define new targets for the development of next-generation drugs that will both prevent and treat malaria.
|Magistrado, Pamela A; Corey, Victoria C; Lukens, Amanda K et al. (2016) Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes. ACS Infect Dis 2:816-826|
|LaMonte, Gregory; Lim, Michelle Yi-Xiu; Wree, Melanie et al. (2016) Mutations in the Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL) Confer Multidrug Resistance. MBio 7:|
|Corey, Victoria C; Lukens, Amanda K; Istvan, Eva S et al. (2016) A broad analysis of resistance development in the malaria parasite. Nat Commun 7:11901|
|Hovlid, Marisa L; Winzeler, Elizabeth A (2016) Phenotypic Screens in Antimalarial Drug Discovery. Trends Parasitol 32:697-707|
|Swann, Justine; Corey, Victoria; Scherer, Christina A et al. (2016) High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria. ACS Infect Dis 2:281-293|
|Plouffe, David M; Wree, Melanie; Du, Alan Y et al. (2016) High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission. Cell Host Microbe 19:114-26|
|Bertin, Matthew J; Demirkiran, Ozlem; Navarro, Gabriel et al. (2016) Kalkipyrone B, a marine cyanobacterial Î³-pyrone possessing cytotoxic and anti-fungal activities. Phytochemistry 122:113-8|
|Ng, Caroline L; Siciliano, Giulia; Lee, Marcus C S et al. (2016) CRISPR-Cas9-modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs. Mol Microbiol 101:381-93|
|Goldgof, Gregory M; Durrant, Jacob D; Ottilie, Sabine et al. (2016) Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor. Sci Rep 6:27806|
|Lehmann, Jason S; Corey, Victoria C; Ricaldi, Jessica N et al. (2016) Whole Genome Shotgun Sequencing Shows Selection on Leptospira Regulatory Proteins During in vitro Culture Attenuation. Am J Trop Med Hyg 94:302-13|
Showing the most recent 10 out of 22 publications